InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (March 2015)
19 slides from InMed Pharmaceuticals's investor presentation, March 2015
Slide 1: Corporate Presentation
CORPORATE PRESENTATION March 2015
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including statements concerning anticipated clinical development activities, the potential benefits of product candidates and anticipated market opportunities. All statements other than statements of historical fact ar
Slide 3: InMed Overview
InMed Overview Our Vision: InMed was founded as a drug discovery and development company to offset and reduce the major challenges of modern biotech/pharma companies: 1. Development Time 2. Development Cost 3. Risk of Attrition Our drug therapies have an accelerated development pathway from tradit
Slide 4: Proprietary Platform Technology
Proprietary Platform Technology Intelligent Cannabinoid Drug Design Platform “IDP” “IDP” is a proprietary bioinformatics tool/algorithm that identifies individual chemical compounds from the cannabis & non-cannabis plants, which can be targeted to develop therapies for specific diseases and conditio
Slide 5: Current Product Pipeline
Current Product Pipeline OCULAR DISEASES CTI-085 (GLAUCOMA) OCULAR ALLERGIES PAIN AND INFLAMMATION CTI-091 (ARTHRITIS) OROFACIAL DERMATOLOGY INM-750 (EPIDERMOLYSIS =) BULLOSA)
Slide 6: Product Pipeline by Q1 2016 (estimated)
Product Pipeline by Q1 2016 (estimated) Upon execution of the above research projects InMed will have the following resources developing our Therapies: 4 labs, 12 Ph.D.’s, 7 Research Associates and 6 lab technicians 6
Slide 7: Glaucoma Market
Glaucoma Market Glaucoma represents $4.5B of global ophthalmic market (EU/US/JPN) Pipeline of glaucoma treatments is relatively weak compared to other treatment areas Xalatan/Xalacom, Travatan and Lumigan accounted for 50% The patent of Pfizer’s Xalatan expired in 2011 Glaucoma is the seco
Slide 8: Uniqueness of CTI085 – Glaucoma Treatment and its Nanoparticle Based Drug Delivery System
Uniqueness of CTI085 – Glaucoma Treatment and its Nanoparticle Based Drug Delivery System Proprietary Mixture of Active Ingredients from Cannabis plants Innovative Delivery System for Clinical applications No CNS, CV & Irritation Safety Issue Problem: Glaucoma suffer exceptionally high rates of medi
Slide 9: Arthritis Market Opportunity
Arthritis Market Opportunity Autoimmune disease that causes chronic joint inflammation. Also causes inflammation of the tissue around the joints and other organs in the body. 55 million people in North America alone suffer from arthritis. Arthritis is the leading cause of disability in the U
Slide 10: About CTI-091 – Arthritis/Inflammation Treatment
About CTI-091 – Arthritis/Inflammation Treatment Designed to relieve joint pain and swelling associated with arthritis and joint disease Proprietary mixture of cannabinoids and non-cannabis based active ingredients Proof-of-concept studies showed suppression of IL-6 by human macrophages Deve
Slide 11: R & D Partners
R & D Partners University of British Columbia Department of Chemical & Biological Engineering Vancouver Campus 2360 East Mall Vancouver, BC Canada V6T 1Z3 University of Debrecen Research Center for Molecular Medicine, Department of Physiology 1H-4032 Debrecen, Nagyerdei krt. 98 Hungary The Universit
Slide 12: Current & Proposed Target Areas
Current & Proposed Target Areas Ocular Diseases Inflammation/Pain • Glaucoma (CTI-085) • Arthritis (CTI-091) • Ocular Allergies • Orofacial Primary Focus Orphan Disease Metabolic Disease • EBS- (INM-750) • Diabetes • Huntington’s • Obesity • Epilepsy Secondary Focus Dermatology Oncology • Skin squam
Slide 13: Significantly Reduces the Drug Development Time Compared to Traditional Drug Development
Significantly Reduces the Drug Development Time Compared to Traditional Drug Development Health Canada Target Lead Lead Preclinical Clinical Trials Approval Identification Identification Optimization Studies (Phase I,II,II) (10-15 yrs.) Traditional Drug Development Pathway Phase I*, II & III Health
Slide 14: InMed's Accelerated Drug Development Process
InMed’s Accelerated Drug Development Process Impact of GW Pharma’s IDP bioinformatics Clinical Trials based platform (Sativex) Network Based Approach for Future Discovery 4- years to > 3000 Approval subjects (Bayer AG) in clinical trials Innovative Drug Delivery System No side effects or withdrawal
Slide 15: Major Pharmaceuticals Involved in Cannabinoid R & D and Commercialization
Major Pharmaceuticals Involved in Cannabinoid R & D and Commercialization 16
Slide 16: Team
TEAM Craig Schneider, B.A. – Chief Executive Officer 20 years of extensive experience in Capital market financing business development & strategic planning with public companies in Technology, Biotechnology and Resource sectors. Co-founder of Magnum Uranium, a TSX.V company which was purchased b
Slide 17: Team con't
TEAM con’t Peter Huang, M.Sc., BSc – Senior Bioinformatician Mr. Huang has over 17 years of experience Bioinformatics, software development and scientific research Mr. Huang’s experience spans multiple disciplines within computer and biological sciences, including plant mutation discoveries and
Slide 18: Capital Structure
Capital Structure CSE: IN Symbol: OTCQB: IMLFF Share I/O: 52.8 Million Warrants: 12.7 Million Options: 4.2 Million Fully-Diluted: 69.7 Million Market Capitalization: CDN $18.5 Million as of March 4, 2015 19
Slide 19: InMed Pharmaceuticals Inc.
Contact Information InMed Pharmaceuticals Inc. #350-409 Granville Street, Vancouver, BC Canada, V6C 1T2 Tel: 604.669.7207 Fax: 604.683.2506 www.inmedpharma.com 20
InMed Pharmaceuticals — Investor Presentation (March 2015) on 6ix